FDA Warning Letter to D&H Medical Services Over Ozempic and Mounjaro Ingredient Comparisons
On June 8, 2026, FDA issued a warning letter to D&H Medical Services after a March 2026 review of dhmedicalcenter.com, which offers compounded semaglutide and tirzepatide products. FDA cites claims including "Same ingredient as Ozempic®," "Same ingredient as Rybelsus®," and "Same ingredient as Mounjaro®" for compounded semaglutide and tirzepatide products, saying the claims represent unapproved compounded products as FDA-approved or evaluated for safety and effectiveness when they have not been. FDA requested a written response within 15 business days.
What this means"Same active ingredient" marketing can blur the line between an FDA-approved drug and a compounded copy that has never been through FDA review — a distinction worth understanding before ordering through any telehealth platform.
Source: FDA original ↗